A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy

Abstract Background Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency. We sought to identify doses of RMD that were safe and induced HIV-1 expression. Methods Enrollees had HIV-1 RNA

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2021-08, Vol.224 (4), p.648-656
Main Authors: McMahon, Deborah K, Zheng, Lu, Cyktor, Joshua C, Aga, Evgenia, Macatangay, Bernard J, Godfrey, Catherine, Para, Michael, Mitsuyasu, Ronald T, Hesselgesser, Joseph, Dragavon, Joan, Dobrowolski, Curtis, Karn, Jonathan, Acosta, Edward P, Gandhi, Rajesh T, Mellors, John W
Format: Article
Language:English
Subjects:
Acetylation
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Antiretroviral therapy
CD4 antigen
CD4 Lymphocyte Count
Clinical trials
Depsipeptides - therapeutic use
Drug therapy
Histone deacetylase
Histone Deacetylase Inhibitors - therapeutic use
Histone H3
HIV
HIV Infections - drug therapy
HIV Seropositivity
Human immunodeficiency virus
Humans
Latency
Lymphocytes
Lymphocytes T
Lysine
Neutropenia
Pharmacodynamics
Phosphorylation
Placebos
Positive Transcriptional Elongation Factor B
Ribonucleic acid
RNA
RNA, Viral
Viremia
Viremia - drug therapy
Virus Latency - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency. We sought to identify doses of RMD that were safe and induced HIV-1 expression. Methods Enrollees had HIV-1 RNA
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa777